

Jazz Pharmaceuticals plc  
 Form 3  
 August 07, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â McGill Iain (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 07/31/2014	3. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)	5. If Amendment, Date Original Filed(Month/Day/Year)
---	--	--	--	--

C/O JAZZ  
 PHARMACEUTICALS  
 PLC,Â CONNAUGHT HOUSE,  
 1 BURLINGTON RD, FL. 4  
 (Street)

Director  10% Owner  
 Officer  Other  
 (give title below) (specify below)  
 Head of EUSA Int'l & SVP

DUBLIN 4,Â L2Â  
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	27,553 <sup>(1)</sup>	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
---	---	--	---------------------------	----------------------	--

Edgar Filing: Jazz Pharmaceuticals plc - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Nonstatutory Stock Option (right to buy)	Â (2)	08/08/2022	Ordinary Shares	22,500	\$ 46.83	D	Â
Nonstatutory Stock Option (right to buy)	Â (3)	03/04/2023	Ordinary Shares	8,500	\$ 59.13	D	Â
Nonstatutory Stock Option (right to buy)	Â (4)	02/26/2024	Ordinary Shares	11,500	\$ 166.62	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
McGill Iain C/O JAZZ PHARMACEUTICALS PLC CONNAUGHT HOUSE, 1 BURLINGTON RD, FL. 4 DUBLIN 4, L2	Â	Â	Â Head of EUSA Int'l & SVP	Â

## Signatures

/s/ Larissa Schwartz as attorney in fact for Iain McGill 08/07/2014

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - (1) Including 25,250 restricted stock units ("RSUs") granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share upon the vesting of the unit. Of the 25,250 RSUs, 15,000 RSUs vest in three equal annual installments from August 9, 2014 to August 9, 2016, 4,500 RSUs vest in three equal annual installments from March 5, 2015 to March 5, 2017, and 5,750 RSUs vest in four equal annual installments from February 27, 2015 to February 27, 2018.
  - (2) This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to this option vested with respect to 1,666 shares and vest with respect to 20,834 shares in equal monthly installments from August 9, 2014 to August 9, 2016.
  - (3) This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to this option vested with respect to 750 shares and vest with respect to 7,750 shares in equal monthly installments from September 5, 2014 to March 5, 2017.
  - (4) This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. 1/4th of the ordinary shares subject to this option vest on February 27, 2015 and the remainder vest in equal monthly installments from March 27, 2015 to February 27, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.